---
schema_version: "secwatch.filing_event.v1"
accession: "0000914475-22-000032"
form_type: "8-K"
ticker: "NBIX"
cik: "0000914475"
company_name: "NEUROCRINE BIOSCIENCES INC"
filed_at: "2022-05-25T23:59:59+00:00"
generated_at: "2026-06-25T07:26:17.807018+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Neurocrine Biosciences repurchases $179.4M of convertible notes, reduces debt by ~60% over two years

## Summary
- Repurchased $179.4M principal of 2.25% Convertible Senior Notes due 2024 for ~$224M cash plus stock-price-based component and accrued interest.
- After repurchase, $201.8M principal remains outstanding; reduced from initial $517.5M.
- CFO states debt reduction of ~60% over two years aims to minimize shareholder dilution.
- Repurchases expected to close by June 14, 2022 under separate private agreements.

## SEC filing metadata
- accession: 0000914475-22-000032
- form_type: 8-K
- ticker: NBIX
- cik: 0000914475
- company_name: NEUROCRINE BIOSCIENCES INC
- filed_at: 2022-05-25T23:59:59+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/914475/000091447522000032/0000914475-22-000032-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/914475/000091447522000032/nbix-20220524.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000914475-22-000032
- JSON: https://secwatch.observer/filing/0000914475-22-000032.json
- Plain text: https://secwatch.observer/filing/0000914475-22-000032.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.